← Eichor
Study identifier: NCT07266116 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients

Condition: Systemic Light Chain Amyloidosis  ·  Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

PhasePhase 1/Phase 2
Planned participants70
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

This study is a clinical trial aimed at the marketing of TQB2934 for injection. The project plans to enroll 70 subjects, including 13-21 subjects in Phase Ib, to evaluate the safety and preliminary efficacy, pharmacokinetic (PK) characteristics, immunogenicity, and pharmacodynamic (PD) of TQB2934 for injection in subjects with systemic light chain amyloidosis, and to determine the recommended Phase II dose (RP2D). The Phase II plan involves enrolling 49 subjects, aiming to demonstrate that in adult subjects with relapsed/refractory systemic light chain amyloidosis who have previously received treatment with daratumumab and bortezomib, TQB2934 for injection significantly improves the hematological complete response (CR) rate compared to historical controls. The primary endpoint is the optimal hematological CR rate.

This description comes directly from the study's public registry record.

Talk to the study team

Jin Lu, Doctor  ·  13311491805  ·  jinllu@sina.com

Always discuss trial participation with your own doctor first.

Locations (27)

Peking University First HospitalBeijing, Beijing Municipality, ChinaNot Yet Recruiting
Peking University People's HospitalBeijing, Beijing Municipality, ChinaRecruiting
Southwest Hospital, Third Military Medical University (Army Medical University)Chongqing, Chongqing Municipality, ChinaNot Yet Recruiting
Fujian Medical University Union HospitalFuzhou, Fujian, ChinaNot Yet Recruiting
The First Affiliated Hospital, Sun Yat-sen UniversityGuangzhou, Guangdong, ChinaNot Yet Recruiting
Guangzhou First Municipal People's HospitalGuangzhou, Guangdong, ChinaNot Yet Recruiting
Peking University ShenZhen HospitalShenzhen, Guangdong, ChinaNot Yet Recruiting
The Affiliated Hospital of Guizhou Medical UniversityGuiyang, Guizhou, ChinaNot Yet Recruiting
Affiliated Hospital of Hebei UniversityBaoding, Hebei, ChinaNot Yet Recruiting
The First Affiliated Hospital of Harbin Medical UniversityHarbin, Heilongjiang, ChinaNot Yet Recruiting
Anyang People's HospitalAnyang, Henan, ChinaNot Yet Recruiting
The First Affiliated Hospital of Zhengzhou UniversityZhengzhou, Henan, ChinaNot Yet Recruiting

+ 15 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07266116